-
公开(公告)号：KR1020020060115A
公开(公告)日：2002-07-16
申请号：KR1020020027396
申请日：2002-05-17
Applicant: 한국과학기술연구원
IPC: A61K31/335
Abstract: PURPOSE: A pharmaceutical composition containing hematein which is obtainable by extraction of Heartwood of Caesalpinia sappan or commercially as an active ingredient is provided. Because the hematein exhibits LDL-antioxidant activity, remarkably reduces cholesterol in blood and strongly inhibits liver microsome ACAT activity, the composition can be effectively used in prevention and therapeutic treatment of atherosclerosis and hyperlipidemia. CONSTITUTION: The composition for preventing and treating atherosclerosis and hyperlipidemia in mammals contains an effective amount of hematein and a pharmaceutically acceptable carrier as an active component. The hematein inhibits the activity of acyl-CoA : cholesterol acyltransferase or acts as LDL-antioxidant to give an effect on preventing and treating hyperlipidemia.
Abstract translation: 目的：提供含有作为活性成分的可以通过提取凯萨金（Caesalpinia sappan）心材或商业获得的含有hematein的药物组合物。 由于唾液酸显示低密度脂蛋白抗氧化活性，显着降低血液中的胆固醇，强烈抑制肝微粒体ACAT活性，可有效用于动脉粥样硬化和高脂血症的预防和治疗。 构成：用于预防和治疗哺乳动物动脉粥样硬化和高脂血症的组合物含有有效量的hematein和药学上可接受的载体作为活性成分。 半乳糖苷抑制酰基辅酶A：胆固醇酰基转移酶的活性或作为低密度脂蛋白抗氧化剂，以预防和治疗高脂血症。
-
2.发明公开네오헤스페리딘 디하이드로칼콘을 포함하는 동맥경화증,고지혈증, 간 질환, 고혈당증의 예방 및 치료용 조성물 失效含有NEOHESPERIDIN DIHYDROCHALCONE的组合物可用于预防和治疗ARTERIOSCLEROSIS，HYPERLIPEMIA，肝脏疾病和GLYCOSEMIA
公开(公告)号：KR1020010007624A
公开(公告)日：2001-01-26
申请号：KR1020000058788
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
Abstract translation: 目的：提供通常用作甜味剂的含有新皮质激素二氢查耳酮的组合物，用于预防和治疗动脉硬化，高脂血症，肝脏疾病和糖血症。 构成：通过从葡萄柚的外层或外层提取或通过化学改变柚皮苷获得新的皮肤色素二氢查耳酮（C28H36O15，M.W.612.60），并且比单位重量的糖更甜1,500-2000倍。 因此，它通常用作不是药用材料的甜味剂。 将包含有效量的新橙皮苷二氢查耳酮，即0.1至500mg / kg，优选1至100mg / kg每天的组合物口服或局部施用于患者，并且施用量可以由患者的年龄， 体重，性别，健康，饮食，疾病严重程度等。 含有新橙皮苷二氢查耳酮的组合物可以以diosmin的0.01〜20重量％，优选0.1〜5重量％的量添加到食品和饮料中。
-
公开(公告)号：KR1020000058218A
公开(公告)日：2000-09-25
申请号：KR1020000028976
申请日：2000-05-29
Applicant: 한국과학기술연구원
IPC: A61K31/35
Abstract: PURPOSE: A composition containing naringin or naringenin for inhibition of the platelet coagulation is provided, which prevents coagulation of platelets caused by exposed collagen when blood vessel endothelial cells is damaged; so which can prevents and cures formation of atheroma, or thrombosis; and which can be used in a medicine and food. CONSTITUTION: A naringin or naringenin is extracted from oranges(a grapefruit, a citron, a lemon, a orange, etc) or manufactured from well-known synthetic process. A pharmaceutical composition as an inhibitor to platelet coagulation comprises of naringin or naringenin as an effective ingredient and pharmaceutically acceptable carriers, which can also contains diluents, disintegrators, sweeteners, lubricants, perfume; and which can be made in the form of tablets, capsules, powders, suspensions, emulsions, syrup, solution or parenteral preparations. A dosage of the composition for inhibition of the platelet coagulation containing naringin or naringenin is 0.5-100mg/kg, desirably 2-10mg/kg. The naringin or naringenin can be added in food or beverages with same purposes.
Abstract translation: 目的：提供含有柚皮苷或柚皮素抑制血小板凝集的组合物，可防止血管内皮细胞损伤时由胶原蛋白引起的血小板凝结; 因此可以预防和治愈动脉粥样化的形成或血栓形成; 并可用于医药和食品。 构成：从橘子（葡萄柚，柚子，柠檬，橙子等）中提取柚皮苷或柚皮素，或由熟知的合成过程制成。 作为血小板凝血抑制剂的药物组合物包含柚皮苷或柚皮苷作为有效成分和药学上可接受的载体，其还可以含有稀释剂，崩解剂，甜味剂，润滑剂，香料; 并且其可以以片剂，胶囊，粉末，悬浮液，乳剂，糖浆，溶液或肠胃外制剂的形式制成。 用于抑制含有柚皮苷或柚皮苷的血小板凝血的组合物的剂量为0.5-100mg / kg，优选为2-10mg / kg。 柚皮苷或柚皮素可加入具有相同目的的食品或饮料中。
-
4.发明公开탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 无效包含从鞣剂衍生的鞣制或酚醛化合物的组合物，用于预防和治疗高脂血症，肠梗塞和肝病
公开(公告)号：KR1020000019718A
公开(公告)日：2000-04-15
申请号：KR1019980037961
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/045
CPC classification number: A23G3/368 , A21D2/14 , A21D2/145 , A21D2/181 , A21D2/36 , A23C9/152 , A23F3/14 , A23L2/56 , A23L33/105 , A61K31/70 , Y10S514/824 , A61K31/35 , A61K31/19 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract translation: 目的：提供包含单宁衍生的单宁或酚型化合物的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有有效量的单宁，没食子酸，鞣花酸或其混合物; 和药学上可接受的载体。 功能性食品或饮料包含0.01-20重量％，优选0.1-5重量％的单宁，没食子酸，鞣花酸或其混合物。 单宁，没食子酸和鞣花酸降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血脂中的血清浓度，抑制肝细胞损伤 并形成脂肪肝。 单宁，没食子酸和鞣花酸强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面。
-
公开(公告)号：KR1020000000753A
公开(公告)日：2000-01-15
申请号：KR1019980020562
申请日：1998-06-03
Applicant: 한국과학기술연구원
IPC: A61K31/35 , A61K31/715
CPC classification number: A23L33/10 , A23L2/38 , A23V2002/00 , A23V2200/30 , A61K31/352 , A61K31/704
Abstract: PURPOSE: A composition is provided to help to improve the blood flow by preventing a platelet cohesion and a formation of a thrombus at the same time. CONSTITUTION: The hesperidins or the hesperetin is effective to prevent and treat the sclerosis of the arteries by the platelet cohesion, and to improve of the blood flow by preventing the platelet cohesion generated by collagen. The composition for the platelet cohesion prevention is able to prescribe as a non-oral administration or to prescribe as an oral administration, and to prescribe the hesperidins or the hesperetin 0.5 mg or 100 mg for 1 kg per a day.
Abstract translation: 目的：提供一种组合物，以帮助通过同时预防血小板凝聚和形成血栓来改善血流量。 构成：橙皮苷或橙皮素通过血小板凝聚力预防和治疗动脉硬化有效，并且通过防止胶原产生的血小板凝聚力来改善血流量。 用于血小板凝聚防止的组合物可以作为非口服给药或作为口服给药开处方，并且将每天1kg的橙皮苷或橙皮素0.5mg或100mg开处方。
-
Patent Agency Ranking6.发明授权야생종 담배의 병발생관련단백질-1 및 글루칸 가수분해효소 유전자 및 이를 이용한 식물병 저항성 유도물질의 탐색방법 失效NICOTIANA GLUTINOSA的PR-1和BET-1,3-GLUCANASE基因及其使用该植物病毒感染耐药性的方法
-
公开(公告)号：KR100145940B1
公开(公告)日：1998-08-17
申请号：KR1019950011788
申请日：1995-05-13
Applicant: 한국과학기술연구원
IPC: A61K31/255
Abstract: 본 발명은 마늘(Alium sativum L.)로부터 분리된 하기 구조식 (I)의 항진균 물질 KRIBB-BP004, 마늘로부터 이의 분리 정제 방법 및 KRIBB-BP004를 활성 물질로서 포함하는 항진균제 조성물에 관한 것이다.
-
公开(公告)号：KR1019970074933A
公开(公告)日：1997-12-10
申请号：KR1019960016412
申请日：1996-05-16
Applicant: 한국과학기술연구원
IPC: C12N15/29
Abstract: 본 발명은 담배로부터 유도 발현되는 메탈로티오네인(metallotionein) 단백질에 관한 것으로, 식물의 병원체 또는 물리적인 상처에 의해서 야생종 담배로부터 발현 유도되는 메탈로티오네인 단백질은 식물체의 병저항성 유도물질 탐색으로 식물체의 병저항성 발현을 확인할 수 있고, 식물체에 가해지는 상처에 대한 방어기작을 조사할 수 있는 표지로서 이용되어 식물체의 스트레스에 대한 저항성 식물의 개발 및 이의 생물학적 치료도 가능하리라 본다.
-
公开(公告)号：KR1019970027037A
公开(公告)日：1997-06-24
申请号：KR1019950041207
申请日：1995-11-14
Applicant: 한국과학기술연구원
IPC: C07C37/08
Abstract: 본 발명은 아실-코에이 : 콜레스테롤 아실트랜스퍼라제(Acyl-CoA : Cholesterol Acyltransferase : ACAT)의 활성을 특이적으로 저해하는 신규한 페놀계 화합물 및 이의 제조방법에 관한 것으로, 후박잎(Magnolia Ovobata Thunb)을 유기용매로 추출하고 정제하여 제조한 하기 구조식을 갖는 페놀류 화합물은 고콜레스테롤 혈증에 기인한 심혈관질환의 예방 및 치료에 유용하게 사용될 수 있다 :
(여기에서 R 및 R'는 각각 독립적으로 수소 또는 하기 구조식을 갖는 그룹으로, 단 R 및 R'는 같지 않고,
R
1 및 R
2 는 각각 독립적으로 수소 또는 히드록시기이다).-
公开(公告)号：KR1019970010757A
公开(公告)日：1997-03-27
申请号：KR1019950025225
申请日：1995-08-17
Applicant: 한국과학기술연구원
IPC: C07D493/08 , C12P17/04
Abstract: 본 발명은 미생물 대사산물로부터 분리되어 콜레스테릴 에스테르 전이 단백질 저해 활성을 나타내는 신규 테트라사이클릭 화합물 및 그의 제조방법에 관한 것으로, 본 발명에 따라 토양으로부터 채취하여 분리 동정한 곰팡이 균주 트리코세시움 로지움(Trichothecium roseum) F1064 (KCTC 8676P)의 대사 산물로부터 분리되거나 이로부터 변형된 테트라사이클릭 화합물 KRIBB-BP005d, m, w 및 wOH는 CETP를 저해하여 혈액내 콜레스테롤 및 저밀도 지질단백질의 수치를 감소시킬 수 있으므로, 동맥경화증을 비롯한 각종 심혈관 질환의 예방 및 치료제로서 이용될 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
78
records
(took 0.027 seconds)
